会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Plasminogen activator covalently bonded to a porous body of
.beta.-tricalcium phosphate
    • 共价键合到β-磷酸三钙的多孔体上的纤溶酶原激活物
    • US5491082A
    • 1996-02-13
    • US246940
    • 1994-05-20
    • Takahiro SuzukiSukezo KawamuraMotohiro ToriyamaYoshiyuki YokokawaYukari KawamotoYasuharu HakamatsukaHiroyuki Irie
    • Takahiro SuzukiSukezo KawamuraMotohiro ToriyamaYoshiyuki YokokawaYukari KawamotoYasuharu HakamatsukaHiroyuki Irie
    • A61K38/00C12N9/72C12N11/14A61K38/48
    • C12N9/6456C12N11/14A61K38/00
    • A plasminogen activator such as urokinase or tissue plasminogen activator is covalently bonded to a porous body composed of calcium phosphate to form a plasminogen activator-porous body complex. The tricalcium phosphate can be .alpha.-tricalcium phosphate, .beta.-tricalcium phosphate, hydroxyapatite, tetracalcium phosphate, octacalcium phosphate and mixtures thereof. In a preferred embodiment, .beta.-tricalcium phosphate which has excellent biocompatibility with the body or a mixture of .beta.-tricalcium phosphate and hydroxyapatite is used. Preferably, synthetic calcium phosphate is used is to avoid impurities contained by natural calcium phosphate. Covalent bonding is by crosslinking with glutaraldehyde, bismaleimides, dihalogenic aryls or diisocyanates, or by using cyanogen bromide, diazotization or periodic acid. The complex can be filled into a column to form a bioreactor. A granular complex can be intravascularly injected into the blood of a patient to provide thrombotic activity for a long period of time. In another embodiment, a complex of a predetermined shape can be implanted to provide thrombotic activity.
    • 纤维蛋白溶酶原激活剂如尿激酶或组织纤溶酶原激活剂共价键合到由磷酸钙组成的多孔体上以形成纤溶酶原激活剂多孔体复合体。 磷酸三钙可以是α-磷酸三钙,β-磷酸三钙,羟基磷灰石,磷酸四钙,磷酸八钙及其混合物。 在优选的实施方案中,使用与身体具有优异生物相容性的β-磷酸三钙或磷酸β-磷酸钙和羟基磷灰石的混合物。 优选地,合成磷酸钙是为了避免天然磷酸钙含有的杂质。 共价键是通过与戊二醛,双马来酰亚胺,二卤代芳基或二异氰酸酯交联,或通过使用溴化氰,重氮化或高碘酸进行交联。 复合物可以填充到柱中以形成生物反应器。 颗粒状复合物可以血管内注射到患者的血液中以长时间提供血栓形成活性。 在另一个实施方案中,可以植入预定形状的复合物以提供血栓形成活性。
    • 2. 发明授权
    • Method of preparing calcium phosphate
    • 磷酸钙的制备方法
    • US5322675A
    • 1994-06-21
    • US4777
    • 1993-01-14
    • Yasuharu HakamatsukaHiroyuki IrieSukezo KawamuraMotohiro Toriyama
    • Yasuharu HakamatsukaHiroyuki IrieSukezo KawamuraMotohiro Toriyama
    • C01B25/32C04B35/447
    • C04B35/447C01B25/327
    • Powdery calcium carbonate and a powdery dihydrate of calcium monohydrogenohosphate are weighed to get a Ca/P ratio of 1.45 to 1.67. The powdery mixture thus prepared is then added pure water at a temperature of 30.degree. C. or higher to obtain an aqueous slurry having a concentration of about 10% by weight. Thereafter, the aqueous slurry is subjected to a rotational attrition by using a ball mill to conduct a mechanochemical reaction of the calcium carbonate with the dihydrate of calcium monohydrogenphosphate. The slurry is then dried completely at 80.degree. C., followed by pulverization to yield a dry powder of calcium phosphate hydrate. The dry powder is calcinated at a temperature ranging from 720.degree. to 1,150.degree. C. for 1-10 hours or more to give calcium phosphate powder, which is molded in a desired shape and is sintered at a certain temperature to obtain a sintered body of calcium phosphate. The calcium phosphate and the sintered body thereof, thus prepared, have an assured biological safety in that the calcium phosphate is free from hemolysis, antigenicity and cytotoxicity.
    • 称量粉状碳酸钙和一水合磷酸二氢钙粉末,得到1.45〜1.67的Ca / P比。 然后将如此制备的粉末混合物在30℃或更高的温度下加入纯水,得到浓度为约10重量%的含水浆料。 然后,使用球磨机对含水浆料进行旋转磨耗,进行碳酸钙与磷酸一氢钙的二水合物的机械化学反应。 然后将浆液在80℃下完全干燥,随后粉碎,得到磷酸钙水合物的干燥粉末。 将干燥粉末在720〜1150℃的温度下煅烧1-10小时以上,得到磷酸钙粉末,其以所需形状成型并在一定温度下烧结,得到烧结体 磷酸钙 由此制备的磷酸钙及其烧结体具有确保的生物安全性,因为磷酸钙不含溶血,抗原性和细胞毒性。